NCT00045006已完成1 期
Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid - SAHA (MSK390) in Patients With Advanced Solid Tumors and Hematologic Malignancies
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who have advanced cancer.
详细描述
OBJECTIVES:
- Determine the maximum tolerated dose of suberoylanilide hydroxamic acid in patients with advanced solid tumors or hematologic malignancies.
- Evaluate the pharmacokinetic profile of this drug in these patients.
- Determine the effects of this drug on absorption in the fasting and non-fasting states in these patients.
- Determine any anti-tumor effects of this drug in these patients.
- Correlate clinical outcomes with histone acetylation in circulating mononuclear cells and tumor biopsy samples in patients treated with this drug.
OUTLINE: This is a dose-escalation study. Patients are stratified according to disease (solid tumor vs multiple myeloma or lymphoma vs leukemia or myelodysplastic syndromes).
The initial 15-20 patients (in the solid tumor or multiple myeloma or lymphoma stratum) receive suberoylanilide hydroxamic acid (SAHA) IV over 2 hours on day 1 of week 0 and then orally once or twice daily beginning on day 1 of week 1. All remaining patients receive oral SAHA once or twice daily beginning on day 1 of week 1. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
In each stratum, cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •One of the following diagnoses:
- •Histologically confirmed advanced primary or metastatic solid tumor, including, but not limited to, the following:
- •Androgen-independent prostate cancer
- •Breast cancer
- •Ovarian cancer
- •Head and neck cancer
- •Non-small cell lung cancer
- •Bladder cancer
- •Kidney cancer
- •Diagnosis of lymphoma, multiple myeloma, leukemia, or myelodysplastic syndromes (MDS), including, but not limited to, the following:
- •Intermediate-grade or follicular non-Hodgkin's lymphoma
- •Hodgkin's lymphoma
- •Patients with lymphoma or multiple myeloma must be ineligible for peripheral blood stem cell transplantation
- •For patients with solid tumors (except prostate cancer):
- •Disease progression based on development of new lesions or an increase in pre-existing lesions
- •Biochemical marker increase must not be sole criterion for disease progression
- •For prostate cancer patients only:
- •Disease progression based on rising prostate-specific antigen (PSA) values, transaxial imaging, or radionuclide scans
- •Increase in disease-related symptoms must not be sole manifestation of progression
- •Patients receiving an antiandrogen as part of first-line hormonal therapy must show disease progression off of the antiandrogen prior to study
- •Biochemical progression (at least 25% increase over range of values) defined as 1 of the following:
- •Rising PSA documented by at least 3 consecutive measurements obtained at least 1 week apart
- •Rising PSA documented by at least 2 consecutive measurements obtained more than 1 month apart
- •PSA at least 4 ng/mL
- •Testosterone no greater than 50 ng/mL
- •If no prior orchiectomy, must maintain castrate levels of testosterone
- •Disease must be refractory to standard therapy or for which no curative therapy exists
- •No active CNS or epidural tumors
- •Hormone receptor status:
- •Not specified NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Male or female
- •Menopausal status
- •Not specified
- •Performance status
- •Karnofsky 70-100%
- •Life expectancy
- •Not specified
- •Hematopoietic
- •WBC at least 3,500/mm^3
- •Platelet count at least 100,000/mm^3 (patients with solid tumors)
- •Platelet count greater than 25,000/mm^3 (patients with hematologic malignancy)
- •Absolute neutrophil count at least 500/mm^3 (patients with hematologic malignancy)
- •Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- •AST and ALT no greater than 3 times ULN
- •PT no greater than 15 seconds
- •Creatinine no greater than 2.0 mg/dL
- •Cardiovascular
- 另有 30 项未显示
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the UrotheliumLocalized Transitional Cell Cancer of the Renal Pelvis and UreterMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterRegional Transitional Cell Cancer of the Renal Pelvis and UreterTransitional Cell Carcinoma of the BladderNCT00363883National Cancer Institute (NCI)14
已完成
2 期
Vorinostat in Treating Patients With Acute Myeloid LeukemiaAdult Acute Erythroid Leukemia (M6)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Acute Promyelocytic Leukemia (M3)Recurrent Adult Acute Myeloid LeukemiaRefractory Cytopenia With Multilineage DysplasiaSecondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid LeukemiaNCT00305773National Cancer Institute (NCI)37
已完成
1 期
Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid TumorsRecurrent Colon CancerRecurrent Rectal CancerStage III Colon CancerStage III Rectal CancerStage IV Colon CancerStage IV Rectal CancerUnspecified Adult Solid Tumor, Protocol SpecificNCT00138177National Cancer Institute (NCI)54
已完成
2 期
Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid CancerInsular Thyroid CancerRecurrent Thyroid CancerStage II Follicular Thyroid CancerStage II Papillary Thyroid CancerStage IV Follicular Thyroid CancerStage IV Papillary Thyroid CancerThyroid Gland Medullary CarcinomaNCT00134043National Cancer Institute (NCI)19
终止
2 期
Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast CancerRecurrent Breast CancerStage IV Breast CancerMale Breast CancerNCT00132002National Cancer Institute (NCI)14